文献速递血栓与止血

非重型血友病A累积暴露50日后抑制剂发展的治疗相关危险因素:病例对照研究

Treatment-related risk factors for inhibitor development in non-severe hemophilia A after 50 cumulative exposure days: A case-control study.
PubMed 文献 · J Thromb Haemost · 2021-07-19

该病例对照研究从INSIGHT研究中纳入非重型血友病A患者(FVIII:C 2%-40%),分析累积暴露50日(EDs)后抑制剂发展的治疗相关危险因素,并比较早期与晚期抑制剂发展的危险因素差异。结果显示,强化FVIII治疗(峰值治疗、高平均FVIII剂量)与早期和晚期抑制剂风险均相关,手术增加早期病例的抑制剂风险,提示终身治疗过程中需持续警惕。

要点

  • 峰值治疗与早期和晚期抑制剂风险相关, crude OR分别为1.8和4.0。
  • 高平均FVIII剂量(>45 IU/kg/ED)与早期和晚期抑制剂风险相关。
  • 手术增加早期病例的抑制剂风险,对晚期病例影响较弱。

核心结论

  • 强化FVIII治疗仍是非重型血友病A患者累积暴露超过50日后抑制剂发展的危险因素。
  • 终身治疗过程中需持续谨慎。

研究设计与样本

  • 病例对照研究,非重型血友病A患者(FVIII:C 2%-40%)选自INSIGHT研究。
  • 抑制剂阳性患者分为早期(<50 EDs)或晚期(>50 EDs)病例,按出生年份、累积EDs数和中心/国家与1-4名抑制剂阴性对照匹配。
  • 分析抑制剂发展前最后10个EDs期间的治疗强度。

主要发现

  • 共分析63例早期病例和26例晚期病例,分别匹配195名和71名对照。
  • 峰值治疗与早期和晚期抑制剂风险相关( crude OR 1.8, 95%CI 1.0-3.4; 4.0, 95%CI 1.1-14.3),调整平均FVIII剂量后关联略减弱。
  • 高平均FVIII剂量与早期和晚期抑制剂风险相关( crude OR 2.8, 95%CI 1.5-5.1; 4.5, 95%CI 1.2-16.6)。
  • 手术增加早期病例的抑制剂风险,对晚期病例影响较弱。

关键数值与推荐

  • 强化治疗定义为:手术、峰值治疗(连续10个EDs)和高平均FVIII剂量(>45 IU/kg/ED)。
  • 抑制剂阳性患者分为早期(<50 EDs)或晚期(>50 EDs)病例。

临床怎么用

  • 对于非重型血友病A患者,即使累积暴露超过50日,仍需警惕强化FVIII治疗相关的抑制剂风险。
  • 临床应关注峰值治疗、高平均FVIII剂量和手术等治疗相关因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Non-severe hemophilia A patients have a life-long inhibitor risk. Yet, no studies have analyzed risk factors for inhibitor development after 50 factor VIII (FVIII) exposure days (EDs). OBJECTIVES: This case-control study investigated treatment-related risk factors for inhibitor development in non-severe hemophilia A and assessed whether these risk factors were different for early versus late inhibitor development. PATIENTS/METHODS: Non-severe hemophilia A patients (FVIII:C 2%-40%) were selected from the INSIGHT study. Inhibitor-positive patients were defined as early (<50 EDs) or late (>50EDs) cases and matched to 1-4 inhibitor-negative controls by year of birth, cumulative number of EDs, and center/country. We investigated treatment intensity during the last 10 EDs prior to inhibitor development. Intensive treatment was defined as: surgery, peak treatment (10 consecutive EDs), and high mean FVIII dose (>45 IU/kg/ED). Odds ratios (OR) were calculated by logistic regression. RESULTS: Of 2709 patients, we analyzed 63 early and 26 late cases and 195 and 71 respectively matched controls. Peak treatment was associated with early and late inhibitor risk (crude OR 1.8, 95% confidence interval [CI] 1.0-3.4; 4.0, 95%CI 1.1-14.3). This association was slightly less pronounced after adjustment for mean FVIII dose. High mean FVIII dose was also associated with early and late inhibitor risk (crude OR 2.8, 95%CI 1.5-5.1; 4.5, 95%CI 1.2-16.6). Surgery increased inhibitor risk for early cases. This was less pronounced for late cases. CONCLUSIONS: Our findings suggest that intensive FVIII treatment remains a risk factor for inhibitor development in non-severe hemophilia A after more than 50 EDs. Therefore, persistent caution is required throughout the life-time treatment course.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Abdi A, Eckhardt CL, van Velzen AS, et al. Treatment-related risk factors for inhibitor development in non-severe hemophilia A after 50 cumulative exposure days: A case-control study. J Thromb Haemost. 2021. PMID: 34107158. doi:10.1111/jth.15419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。